1-benzyl-5-chloroindole-3-carboxylic acid | 172596-64-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-benzyl-5-chloroindole-3-carboxylic acid
• CAS: 172596-64-4
• 化学式: C₁₆H₁₂ClNO₂
• 分子量: 285.73
• InChiKey: WSQPSZUEBKYERC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-氨乙基)哌啶 、 1-benzyl-5-chloroindole-3-carboxylic acid 在 N,N'-羰基二咪唑 作用下， 生成 1-benzyl-5-chloro-N-(2-piperidin-1-ylethyl)indole-3-carboxamide
  参考文献：
  名称：

  Indole amide derivatives: synthesis, structure–activity relationships and molecular modelling studies of a new series of histamine H1-receptor antagonists

  摘要：

  A number of indole amide derivatives bearing a basic side chain, in which the indole ring replaces the isoster benzimidazole nucleus typical of some well-known antihistamines, were prepared and tested for their H-1-antihistaminic activity. The 1-benzyl-3-indolecarboxamides 32-42 showed antihistaminic (H-1) activity (pA(2) 6-8); the 3-indolylglyoxylylamides 7-16 and the 2-indolecarboxamides 48-56 showed little or no activity. Insertion of the basic side chain of the active 3-indolecarboxamide derivatives into a piperazine ring (compounds 57-59) led to a dramatic loss of activity. All the active compounds proved to be competitive antagonists, since the values of the regression slope were not statistically different from 1. The most active compounds, 32, 33, 38-41, were also tested both in vitro for their anticholinergic activity and in vivo for their ability to antagonize histamine-induced cutaneous vascular permeability in rats. The biological results and the structure-activity relationships of the novel compounds are discussed in the light of molecular modelling studies, taking the molecule of astemizole as a model, and referring to proposed H-1-receptor pharmacophore models. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80044-0
• 作为产物：
  描述：

  5-氯吲哚-3-甲醛 在 potassium permanganate 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 16.0h， 生成 1-benzyl-5-chloroindole-3-carboxylic acid
  参考文献：
  名称：

  Indole amide derivatives: synthesis, structure–activity relationships and molecular modelling studies of a new series of histamine H1-receptor antagonists

  摘要：

  A number of indole amide derivatives bearing a basic side chain, in which the indole ring replaces the isoster benzimidazole nucleus typical of some well-known antihistamines, were prepared and tested for their H-1-antihistaminic activity. The 1-benzyl-3-indolecarboxamides 32-42 showed antihistaminic (H-1) activity (pA(2) 6-8); the 3-indolylglyoxylylamides 7-16 and the 2-indolecarboxamides 48-56 showed little or no activity. Insertion of the basic side chain of the active 3-indolecarboxamide derivatives into a piperazine ring (compounds 57-59) led to a dramatic loss of activity. All the active compounds proved to be competitive antagonists, since the values of the regression slope were not statistically different from 1. The most active compounds, 32, 33, 38-41, were also tested both in vitro for their anticholinergic activity and in vivo for their ability to antagonize histamine-induced cutaneous vascular permeability in rats. The biological results and the structure-activity relationships of the novel compounds are discussed in the light of molecular modelling studies, taking the molecule of astemizole as a model, and referring to proposed H-1-receptor pharmacophore models. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80044-0

文献信息

• NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0746544A1

  公开（公告）日：1996-12-11
• US5877202A
  申请人：——

  公开号：US5877202A

  公开（公告）日：1999-03-02
• [EN] NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS<br/>[FR] NOUVEAUX DERIVES D'INDOLE UTILISES POUR TRAITER DES NEOPLASMES ET DES TROUBLES ASSOCIES AUX OESTROGENES
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：WO1995022524A1

  公开（公告）日：1995-08-24

  (EN) The present invention relates to novel indole derivatives of formula (I), useful in down-regulating estrogen receptor expression. Also included are methods for the treatment of neoplasms or of controlling the growth of a neoplasm in a patient afflicted with a neoplastic disease, especially estrogen-dependent neoplasms such as those associated with breast, ovarian and cervical tissue. Another embodiment of the present invention is a method of prophylactically treating a patient at risk of developing neoplastic disease state. Also provided is a method for treating autoimmune diseases. Also included are pharmaceutical compositions of the novel indole derivatives.(FR) La présente invention se rapporte à de nouveaux dérivés d'indole de la formule (I) qui sont utilisés dans la régulation négative de l'expression des récepteurs d'÷strogènes. L'invention se rapporte également à des procédés de traitement des néoplasmes ou de régulation du développement d'un néoplasme chez un patient atteint d'une maladie néoplasique, notamment des néoplasmes dépendant des ÷strogènes, tels que ceux associés au tissu mammaire, ovarien, et cervical. Selon un autre mode de réalisation de la présente invention, on décrit un procédé de traitement prophylactique d'un patient sujet à développer un état pathologique néoplasique. L'invention se rapporte encore à un procédé de traitement des maladies auto-immunes, ainsi que des compositions pharmaceutiques des nouveaux dérivés d'indole.